Differences in immunity and survival among non-small cell lung cancer patients: a gut microbiota perspective
Key Points
Gut microbiota, particularly bifidobacterium and lactobacillus, enhance tumor immunity and activate t cells.
Patients with higher levels of specific bacteria may show better immune system responses and overall survival.
This observational analysis highlights the role of gut microbiota in supporting immune feedback loops and reducing inflammation.
Findings suggest that targeting gut microbiota could improve treatment strategies for non-small cell lung cancer.
Abstract
In NSCLC, Bifidobacterium and Lactobacillus promote beneficial immune feedback loops by activating T cells and exerting anti-inflammatory effects, thereby supporting antitumor immunity.